Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report

ConclusionsDurvalumab plus tremelimumab combination therapy can lead to fulminant immune-mediated myocarditis. This patient's myocarditis was amenable to treatment with high-dose intravenous steroids and mycophenolate.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research